Chemical activators of ZFP617 utilize various intracellular pathways to modulate the protein's activity. Phorbol 12-myristate 13-acetate (PMA) is one such activator that targets protein kinase C (PKC). Activation of PKC by PMA can lead to the phosphorylation of ZFP617, altering its conformation in a way that influences its function within the cell. Similarly, Ionomycin increases intracellular calcium levels, which in turn can activate calcium-dependent protein kinases that phosphorylate ZFP617. This phosphorylation serves as a regulatory switch to activate ZFP617. Forskolin and its analogs, 8-Bromo-cAMP and Dibutyryl-cAMP, elevate intracellular cAMP levels, which then activate protein kinase A (PKA). PKA can phosphorylate ZFP617, thereby modulating its activity. A23187, also known as Calcimycin, functions similarly to Ionomycin by increasing intracellular calcium and activating kinases that can phosphorylate ZFP617.
Calyculin A and Okadaic Acid are inhibitors of protein phosphatases 1 and 2A, which normally dephosphorylate proteins. By inhibiting these phosphatases, these compounds indirectly keep ZFP617 in a phosphorylated state, maintaining its activity. Thapsigargin contributes to the activation of ZFP617 through a different mechanism; it inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. This rise in calcium can activate kinases that are capable of phosphorylating ZFP617. Brefeldin A disrupts protein transport and can activate stress response pathways, which may involve kinases that phosphorylate ZFP617. Staurosporine, although a potent inhibitor of PKC, at specific concentrations, can activate other kinases that may phosphorylate and activate ZFP617. Bisindolylmaleimide I, primarily a PKC inhibitor, can similarly affect other kinases due to off-target effects, which may also lead to the activation of ZFP617 through phosphorylation. These chemical activators, through their diverse effects on kinases and phosphatases, regulate the phosphorylation status and thus the activity of ZFP617 within cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which is involved in various signaling pathways. Activation of PKC can lead to phosphorylation events that activate ZFP617 by altering its conformation or interaction with other proteins or DNA. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium concentration. Elevated calcium can activate calcium-dependent protein kinases, which may phosphorylate and activate ZFP617. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. PKA can then phosphorylate ZFP617, resulting in its activation. | ||||||
Calcium dibutyryladenosine cyclophosphate | 362-74-3 | sc-482205 | 25 mg | $147.00 | ||
Dibutyryl-cAMP is another cAMP analog that activates PKA. Activation of PKA can lead to phosphorylation of ZFP617, promoting its activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore similar to Ionomycin, and it can increase intracellular calcium, potentially activating kinases that could phosphorylate and activate ZFP617. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Calyculin A is an inhibitor of protein phosphatases 1 and 2A. By preventing the dephosphorylation of proteins, it can indirectly maintain ZFP617 in an activated state through persistent phosphorylation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. This can activate calcium-dependent kinases, which then may phosphorylate and activate ZFP617. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatase 1 and 2A, like Calyculin A. It can maintain ZFP617 in a phosphorylated and active state by inhibiting its dephosphorylation. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts protein transport by inhibiting the exchange of protein ADP-ribosylation factor (ARF). This disrupts cellular signaling, which can lead to activation of stress response pathways. These pathways might involve kinases that phosphorylate ZFP617, leading to its activation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent PKC inhibitor but can also act non-specifically on other kinases at different concentrations. At specific concentrations, it might activate certain kinases that could phosphorylate and thereby activate ZFP617. | ||||||